IL-10 R beta Antibody [Unconjugated]

Recombinant Human IL‑10 (Catalog # 217-IL) inhibits IL‑1 beta secretion in LPS-activated human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner (orange line), as measured by the Human IL‑1 beta /IL‑1F2 Quantikine ELISA Kit (Catalog # DLB50).IL‑1 beta secretion inhibited by Recombinant Human IL‑10 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑10 R beta Antigen Affinity-purified Polyclonal Antibody (Catalog # AF874). The ND50 is typically 2-6 µg/mL in the presence of LPS (0.25 ng/mL).

• Reactivity: Hu
• Applications: WB, Flow, B/N, CyTOF-ready
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-10 R beta Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human IL-10 R beta
  Met20-Ser220
  Accession # Q08334
• Specificity: Detects human IL-10 R beta in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human
  (rh) IL‑20 R alpha , rhIL-10 R, and rhIL-20 R beta is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IL10RB
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.20 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 2.5 ug/10^6 cells
  • Neutralization 2-6 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-10 R beta Antibody [Unconjugated]

• CDw210b antigen
• CDw210b
• CRF2-4IL-10R subunit 2
• CRFB4
• CRFB4human transmembrane receptor protein; cytokine receptor10CDW210B
• D21S58
• D21S66
• IBD25
• IL-10 R beta
• IL-10 receptor subunit beta
• IL10R beta
• IL-10R2
• IL-10R2IL-10R subunit beta
• IL10RB
• IL-10Rb
• interleukin 10 receptor, beta
• Interleukin-10 receptor subunit 2
• interleukin-10 receptor subunit beta
• member 4

Background

IL-10, also known as IL-10 R2, mediates its biological activities via binding to a heteromeric receptor complex consisting of two distinct type II cytokine receptor subunits, the ligand binding IL-10 R alpha and the IL-10 R beta which does not bind IL-10 by itself but is required for signal transduction. The cDNA for human IL-10 R beta encodes a 325 amino acid (aa) residue type I transmembrane precursor protein with a 20 aa signal sequence, a 200 aa extracellular region, a 29 aa transmembrane segment, and a short 76 aa cytoplasmic domain. Within the extracellular region, there are two 100 aa subdomains that resemble the constant region of immunoglobulins. This structural motif is responsible for the alternative designation of IL-10 R beta as CRF2-4 (the 4^th member of the cytokine receptor family class II/2). Human and mouse IL-10 R beta share approximately 69% aa sequence identity. Binding of the non-covalent IL-10 dimer to two IL-10 R alpha chains recruits two
IL‑10 R beta chains resulting in the activation and phosphorylation of the signaling cascade involving JAK1, TYK2, and STAT3. IL-10 R beta  is expressed ubiquitously.
IL‑10 R beta is also a component of the IL-22 receptor complex consisting of the IL-10 R beta chain and IL-22 R, another type II cytokine receptor family member.

1. Donnelly, R.P. et al. (2004) J. Leukoc. Biol. 76:314.
2. Donnelly, R.P. et al. (1999) J. Interferon Cytokine Res. 19:563.
3. Kotenko, S.V. et al. (2000) J. Biol. Chem. 276:2725.
4. Liu, Y. et al. (1994) J. Immunol. 152:1821.
5. Lutfalla, G. et al. (1993) Genomics 16:366.
6. Kotenko, S.V. et al. (1997) EMBO J. 16:5894.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-10 R beta Antibody (AF874)(11)

Publications using AF874

• AA Obajemu, N Rao, KA Dilley, JM Vargas, F Sheikh, RP Donnelly, RS Shabman, EG Meissner, L Prokunina-, OO Onabajo IFN-?4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling J. Immunol., 2017-10-25;0(0):. 2017-10-25 [PMID: 29070670] (Neutralization, Human)
• Trisomy 21 consistently activates the interferon response Elife, 2016-07-29;5(0):. 2016-07-29 [PMID: 27472900] (Western Blot, Human)
• Replication of human norovirus RNA in mammalian cells reveals a lack of interferon response J Virol, 2016-09-12;0(0):. 9/12/2016 [PMID: 27466422]
• Stephan Meller, Jeremy Di Di Domizio, Kui S Voo, Heike C Friedrich, Georgios Chamilos, Dipyaman Ganguly et al. T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26 Nature Immunology 2015-09-01 [PMID: 26168081]
• Chandra P, Bao L, Song K, Aboulnasr F, Baker D, Shores N, Wimley W, Liu S, Hagedorn C, Fuchs S, Wu T, Balart L, Dash S HCV infection selectively impairs type I but not type III IFN signaling. Am J Pathol, 2013-11-09;184(1):214-29. 2013-11-09 [PMID: 24215913] (Flow Cytometry, Human)
• Noelle D. Brodeur, Juliet V. Spencer Antibodies to human IL-10 neutralize ebvIL-10-mediated cytokine suppression but have no effect on cmvIL-10 activity Virus Research 2010-11-01 [PMID: 20728483]
• Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun., 2009-10-01;10(8):702-14. 2009-10-01 [PMID: 19798076] (Western Blot, Human)
• Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine, 2005-07-21;31(2):109-18. 2005-07-21 [PMID: 15899585] (Neutralization, Human)
• Sheikh F, Baurin VV, Lewis-Antes A, Shah NK, Smirnov SV, Anantha S, Dickensheets H, Dumoutier L, Renauld JC, Zdanov A, Donnelly RP, Kotenko SV Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J. Immunol., 2004-02-15;172(4):2006-10. 2004-02-15 [PMID: 14764663] (Neutralization, Human)
• Heuze-Vourc&amp;apos;h N Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells. Cancer Res., 2003-02-15;63(4):766-70. 2003-02-15 [PMID: 12591723] (Flow Cytometry, Human)
• Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol., 2002-12-02;4(1):63-8. 2002-12-02 [PMID: 12469119] (Neutralization, Human)

Bioinformatics

• Gene Symbol: IL10RB
• Uniprot:
  • Q08334()